Age, year, median (range) |
61 (41-80) |
Male sex, n (%) |
14 (58.3) |
Race, n (%) |
|
White |
16 (66.7) |
Black |
6 (25) |
Other |
2 (8.3) |
International staging system at diagnosis, n (% of 17) |
|
I |
7 (41.2) |
II |
5 (29.4) |
III |
5 (29.4) |
Cytogenetics/FISH, n (% of 23) |
|
Standard risk |
12 (52.2) |
High risk |
11 (47.8) |
Time from diagnosis to BiRd, median (range) months |
36.7 (6.6-59) |
Median prior therapy, n (range) |
3 (1-8) |
Prior stem cell transplant, n (%) |
6 (25) |
Prior treatment with bortezomib, n (%) |
13 (54.2) |
Prior treatment with thalidomide, n (%) |
13 (54.2) |
Prior treatment with Rd, n (%) |
24 (100%) |
Best response to Rd, n (%) |
|
PR |
10 (41.7) |
MR |
3 (12.5) |
SD |
7 (29.2) |
PD |
4 (16.7) |
Median duration on Rd, mo, range |
5.2 (1.6-37.8) |